|
Volumn 49, Issue 5, 2001, Pages 687-688
|
Antithrobotic therapy for prevention of pneumonia [6]
a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTICOAGULANT AGENT;
CILOSTAZOL;
CYCLIC AMP PHOSPHODIESTERASE;
PHOSPHODIESTERASE INHIBITOR;
FIBRINOLYTIC AGENT;
TETRAZOLE DERIVATIVE;
AGED;
ANTICOAGULANT THERAPY;
ANTIHYPERTENSIVE THERAPY;
ASPIRATION PNEUMONIA;
BRAIN INFARCTION;
DISEASE SEVERITY;
FEMALE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNE DEFICIENCY;
INCIDENCE;
LETTER;
MAJOR CLINICAL STUDY;
MALE;
RECURRENT DISEASE;
RISK ASSESSMENT;
THROMBOCYTE AGGREGATION INHIBITION;
CEREBROVASCULAR ACCIDENT;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
FOLLOW UP;
PROPORTIONAL HAZARDS MODEL;
RANDOMIZED CONTROLLED TRIAL;
RISK FACTOR;
TREATMENT OUTCOME;
AGED;
CEREBRAL INFARCTION;
CEREBROVASCULAR ACCIDENT;
FIBRINOLYTIC AGENTS;
FOLLOW-UP STUDIES;
HUMANS;
INCIDENCE;
PNEUMONIA, ASPIRATION;
PROPORTIONAL HAZARDS MODELS;
RECURRENCE;
RISK FACTORS;
TETRAZOLES;
TREATMENT OUTCOME;
|
EID: 0034743915
PISSN: 00028614
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1532-5415.2001.49140.x Document Type: Letter |
Times cited : (46)
|
References (5)
|